MOTS-c Peptide: What Is It Studied For?

What Is MOTS-c?

MOTS-c is a mitochondrial-derived microprotein encoded by a short open reading frame within the 12S ribosomal RNA gene of mitochondrial DNA. A 2015 preclinical study published in Cell Metabolism first characterized the 16-amino-acid peptide and reported its role in metabolic signaling — establishing that mitochondria function not only as energy-producing organelles but as active signaling units capable of influencing systemic physiology. The compound's full name, mitochondrial open reading frame of the 12S rRNA-c, is typically shortened to MOTS-c throughout the literature.

---

What Is MOTS-c Studied For?

Research on MOTS-c goes back to 2015 — nearly 10 years — with studies continuing through 2026.

1. Metabolic Homeostasis and Insulin Resistance — The original 2015 preclinical study in mice (Lee et al., Cell Metabolism) reported that MOTS-c administration reduced diet-induced obesity, improved insulin sensitivity, and promoted metabolic homeostasis by activating the AMPK pathway and regulating glucose and lipid metabolism in skeletal muscle.

2. Gestational Diabetes — A 2022 preclinical rodent study (Yin et al., Pharmacological Research) found that MOTS-c relieved hyperglycemia and insulin resistance in a mouse model of gestational diabetes mellitus, suggesting the compound targets metabolic dysregulation associated with pregnancy-related glucose impairment.

3. Skeletal Muscle Function and Atrophy Prevention — A 2026 preclinical mouse study (Kumagai et al., iScience) demonstrated that MOTS-c directly binds and activates casein kinase 2 (CK2), with administration preventing skeletal muscle atrophy and enhancing muscle glucose uptake in a CK2-dependent manner.

4. Ovarian Cancer Progression — A 2024 preclinical study (Yin et al., Advanced Science) reported that MOTS-c suppressed ovarian cancer tumor growth by attenuating USP7-mediated deubiquitination of LARS1, a mechanism linking mitochondrial signaling to tumor biology.

5. Pancreatic Beta-Cell Senescence and Diabetes Delay — A 2025 preclinical mouse study (Kong et al., Experimental & Molecular Medicine) found that MOTS-c levels declined in aging and diabetic pancreatic islets, and that restoring the peptide prevented beta-cell senescence, delaying both type 1 and type 2 diabetes progression in animal models.

All five areas above are supported exclusively by animal or in vitro preclinical data. No human clinical trial results appear in the primary study pool.

---

How Does MOTS-c Work?

MOTS-c operates primarily through mitochondrial-nuclear communication — a retrograde signaling pathway in which mitochondria transmit regulatory information to the nucleus to modulate gene expression. The 2015 Lee et al. mouse study identified AMPK activation as a central mechanism, with downstream effects on fatty acid oxidation and glucose uptake in skeletal muscle.

More recent work has expanded this mechanistic picture. The 2026 Kumagai et al. mouse study identified CK2 as a direct, functional molecular target: MOTS-c physically binds CK2 in cell-free systems and activates it, and these effects were shown to be tissue-specific. This finding provides a concrete biochemical handle for the peptide's metabolic effects in muscle.

A 2025 preclinical study (Li et al., Redox Biology) identified a distinct mechanism in lung endothelial cells: MOTS-c interacts with MYH9, a non-muscle myosin protein, to enable nuclear translocation and transcriptional activation of antioxidant gene programs. That pathway appears relevant to oxidative stress protection rather than metabolic regulation, suggesting MOTS-c operates through context-dependent mechanisms across tissue types.

---

What Does Animal Research Show?

The bulk of published MOTS-c research is preclinical, conducted across mouse and rat models spanning metabolic, oncological, inflammatory, and infectious disease contexts.

The 2015 Lee et al. mouse study established the foundational metabolic profile: mice given MOTS-c resisted high-fat diet-induced weight gain and showed improved insulin signaling. This study also reported that the peptide translocates to the nucleus under metabolic stress — a finding that positioned MOTS-c as a signaling molecule rather than a purely local mitochondrial factor.

In a gestational diabetes model, the 2022 Yin et al. rodent study reported that MOTS-c administration corrected hyperglycemia and improved insulin resistance, extending the metabolic findings into a pregnancy-specific pathological context. Existing therapies for gestational diabetes are limited, which the authors noted as motivation for examining novel mitochondrial signals.

The 2025 Kong et al. mouse study focused on pancreatic islets, reporting that endogenous MOTS-c levels fell in aging and diabetic animals, and that exogenous administration reduced markers of beta-cell senescence. The study examined both type 1 and type 2 diabetes models, with the compound appearing to preserve islet function by countering age-associated mitochondrial dysfunction.

On the musculoskeletal side, the 2026 Kumagai et al. mouse study examined skeletal muscle atrophy, finding that MOTS-c prevented muscle wasting and improved glucose uptake via CK2 activation. The tissue-specificity of these effects — blunted when CK2 activity was pharmacologically suppressed — is a notable mechanistic detail, as it suggests the compound's actions are not uniformly systemic.

A 2025 preclinical study (Li et al., Free Radical Biology & Medicine) examined osteoarthritis in a rodent model and reported that MOTS-c attenuated mitochondrial dysfunction, reduced chondrocyte pyroptosis (an inflammatory form of cell death), and slowed cartilage degradation through an Nrf2-dependent antioxidant mechanism.

The 2025 Li et al. Redox Biology preclinical study addressed lung ischemia-reperfusion injury in the context of cardiopulmonary bypass-induced acute respiratory distress syndrome. MOTS-c administration protected lung endothelial cells against oxidative stress by triggering MYH9-dependent nuclear translocation and upregulating antioxidant transcriptional programs.

The 2024 Yin et al. Advanced Science preclinical study investigated ovarian cancer, reporting that MOTS-c levels were reduced in tumor tissue and that restoring the compound suppressed tumor progression by disrupting USP7-mediated stabilization of LARS1 — a leucyl-tRNA synthetase implicated in cancer cell survival. Two of the eight primary studies in this pool share Yin Yadong as an author; the cancer and gestational diabetes findings represent distinct lines of inquiry from that group.

A 2024 preclinical study with an n of 404 biological samples (Lin et al., Gut) examined hepatitis B virus infection and reported that MOTS-c contributes to antiviral defense by remodeling mitochondrial structure. The study identified the compound as a potential diagnostic marker for chronic hepatitis B and found that it suppressed HBV replication in both cell and animal models.

---

What Does Human Research Show?

The primary study pool used for this article contains no completed human clinical trials of MOTS-c. All mechanistic and efficacy findings described above derive from rodent or cell-based preclinical models.

The 2024 Lin et al. Gut study, which enrolled 404 participants, included human sample analysis for diagnostic marker purposes — examining circulating MOTS-c levels in chronic hepatitis B patients — but was not a therapeutic intervention trial. That observational component provides some translational context but cannot substitute for controlled human efficacy data. Author concentration is worth noting: two of the eight primary studies list Cohen Pinchas and Yin Yadong among their authors, reflecting the relatively small research group conducting much of this work.

Human trials would need to address pharmacokinetics, dosing range, route optimization, and safety in clinical populations before efficacy claims could be evaluated. That work has not been published in peer-reviewed form within the current study pool.

---

What Is Still Unknown About MOTS-c?

Several fundamental questions remain open. The tissue-specificity of MOTS-c's mechanisms — clearly demonstrated in the Kumagai et al. CK2 work — raises questions about which effects dominate in vivo and whether they interact or conflict across organ systems. The antioxidant pathway identified in lung tissue (MYH9-dependent nuclear translocation) and the AMPK-driven metabolic pathway in muscle are distinct; how these coordinate systemically is not yet characterized.

Endogenous regulation is another open area. The Kong et al. 2025 study reported declining MOTS-c levels in aging and diabetic pancreatic tissue, and the Lin et al. 2024 study used circulating levels as a potential diagnostic signal in hepatitis B. Whether declining endogenous MOTS-c is a driver of disease or a downstream consequence — and what governs its regulation — remains unresolved.

Cancer biology adds complexity. The Yin et al. 2024 findings position MOTS-c as a tumor suppressor in ovarian cancer through a specific ubiquitination pathway, but the implications across other cancer types are unknown. Therapeutic exploitation of that mechanism requires understanding how MOTS-c interacts with the broader proteostasis network in tumor environments.

All current evidence is preclinical. Translating rodent metabolic, musculoskeletal, and oncological findings into human models requires trials that have not yet been conducted or published.

---

Where Can I Buy MOTS-c?

MOTS-c is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---